Severity of Sars-Cov-2 Infection in Patients with Hematologic Malignancies: A COVID-19 and Cancer Consortium (CCC19) Registry Analysis

Background: Patients with hematologic malignancy (HM) are hypothesized to be at high risk of poor outcomes with coronavirus disease 2019 (COVID-19), due to disease and therapy-related immunosuppression. Despite this, there are minimal reported data describing the outcomes of HM patients with COVID-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Rubinstein, Samuel, Lynch, Ryan C., Desai, Aakash, Stratton, Catherine, Jha, Alokkumar, Bakouny, Ziad, Schmidt, Andrew, Sica, R. Alejandro, Bhutani, Divaya, Shah, Dimpy P., Wall, Sarah A, Lyman, Gary H., Kuderer, Nicole M., Weiss, Matthias, Warner, Jeremy L., Stockerl-Goldstein, Keith E., Mesa, Ruben, Thompson, Michael A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2020
Materias:
904.Outcomes Research-Non-Malignant Conditions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330211/
http://dx.doi.org/10.1182/blood-2020-141937

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330211/
http://dx.doi.org/10.1182/blood-2020-141937

Ejemplares similares